下腔静脉血栓患者的治疗策略与临床结局:GARFIELD-VTE数据
基于GARFIELD-VTE前瞻性观察性登记研究,比较100例下腔静脉血栓与7629例下肢深静脉血栓患者。下腔静脉血栓患者更年轻、合并活动性癌症比例更高,更多接受单纯肠外抗凝、溶栓或手术/机械干预。24个月全因死亡率更高(13.28 vs 4.91/100人年),但VTE复发率与大出血发生率相近。
要点
- 下腔静脉血栓患者较下肢深静脉血栓患者更年轻且合并癌症比例更高。
- 下腔静脉血栓更多采用单纯肠外抗凝、溶栓或手术/机械干预。
- 下腔静脉血栓24个月全因死亡率更高,部分归因于恶性肿瘤。
核心结论
- 下腔静脉血栓患者24个月全因死亡率高于下肢深静脉血栓患者,该差异仅部分归因于恶性肿瘤。
研究设计与样本
- 比较100例下腔静脉血栓患者与7629例下肢深静脉血栓患者的基线特征、治疗模式和24个月结局。
主要发现
- 下腔静脉血栓患者较下肢深静脉血栓患者更年轻(51.9 vs 59.8岁)。
- 下腔静脉血栓患者活动性癌症(26.0% vs 8.9%)和癌症病史(21.0% vs 12.2%)比例更高,近期创伤或手术比例更低。
- 下腔静脉血栓更多接受单纯肠外抗凝(35.1% vs 15.9%)、溶栓(11.0% vs 3.6%)和手术/机械干预(4.0% vs 1.4%)。
- 24个月全因死亡率(每100人年,95%CI)下腔静脉血栓为13.28(8.57-20.58),下肢深静脉血栓为4.91(4.55-5.3)。
- 24个月VTE复发率(每100人年,95%CI)下腔静脉血栓为4.11(1.85-9.15),下肢深静脉血栓为4.18(3.84-4.55);大出血发生率分别为2.03(0.66-6.31)和1.66(1.45-1.89)。
临床怎么用
- 下腔静脉血栓患者应评估恶性肿瘤并关注高死亡风险,治疗上可考虑更积极的抗凝或干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inferior vena cava (IVC) thrombosis is a rare form of venous thromboembolism (VTE). The optimal treatment strategies and outcomes are unclear in patients with this presentation. OBJECTIVE: We aimed to compare baseline characteristics, treatment patterns and 24-month outcomes in IVC thrombosis patients (n = 100) with lower extremity deep vein thrombosis (LEDVT) patients (n = 7629). METHODS: GARFIELD-VTE is a prospective, observational registry of 10 868 patients with objectively diagnosed VTE from 415 sites in 28 countries. RESULTS: IVC thrombosis patients were younger (51.9 vs. 59.8 years), more frequently had active cancer (26.0% vs. 8.9%) or history of cancer (21.0% vs. 12.2%), and less frequently had recent trauma or surgery than LEDVT patients. IVC thrombosis was more frequently treated with parenteral anticoagulants alone (35.1% vs. 15.9%), whereas patients with LEDVT more commonly received vitamin K antagonists (32.0% vs. 25.8%) or direct oral anticoagulants (49.0% vs. 35.1%). Thrombolysis (11.0% vs. 3.6%) and surgical/mechanical interventions (4.0% vs. 1.4%) were more frequent in IVC thrombosis. At 24-months, the rate per 100 person-years (95% confidence interval) of all-cause mortality was higher in patients with IVC thrombosis than LEDVT (13.28 [8.57-20.58] vs. 4.91 [4.55-5.3]); the incidence of cancer-associated mortality was comparable as was the incidence of VTE recurrence (4.11 [1.85-9.15] vs. 4.18 [3.84-4.55]). Major bleeding was slightly higher in IVC thrombosis (2.03 [0.66-6.31] vs. 1.66 [1.45-1.89]). CONCLUSION: In summary, IVC thrombosis patients have higher all-cause mortality rates than those with LEDVT, a finding only partly attributable to malignancy.
引用
- Cohen O, Ageno W, Farjat AE, et al. Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. J Thromb Haemost. 2021. PMID: 34714962. doi:10.1111/jth.15574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。